Illumina, Inc. revenue
Illumina, Inc.'s revenue was $4.34bn in fiscal 2025, down 0.7% on the year before. Since fiscal 2009 ($666m) it has grown at a compound 12.4% a year. Over the last twelve months it was $4.54bn.
Revenue history
| Fiscal year | 2009Jan 2010 | 2010Jan 2011 | 2011Jan 2012 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Jan 2016 | 2016Jan 2017 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Jan 2021 | 2021Jan 2022 | 2022Jan 2023 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 666 | 903 | 1,056 | 1,149 | 1,421 | 1,861 | 2,220 | 2,398 | 2,752 | 3,333 | 3,543 | 3,239 | 4,526 | 4,584 | 4,504 | 4,372 | 4,343 | 4,538 |
| Growth on the year before | — | +35.5% | +16.9% | +8.8% | +23.7% | +31.0% | +19.3% | +8.0% | +14.8% | +21.1% | +6.3% | −8.6% | +39.7% | +1.3% | −1.7% | −2.9% | −0.7% | — |
| Gross profit | 454 | 602 | 709 | 774 | 912 | 1,298 | 1,549 | 1,666 | 1,826 | 2,300 | 2,467 | 2,203 | 3,154 | 2,972 | 2,744 | 2,861 | 2,870 | 3,080 |
| Gross margin | 68.1% | 66.6% | 67.2% | 67.4% | 64.2% | 69.7% | 69.8% | 69.5% | 66.4% | 69.0% | 69.6% | 68.0% | 69.7% | 64.8% | 60.9% | 65.4% | 66.1% | 67.9% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Sequencing | $4B | 91.8% | ▼ 0.2% |
| Microarray | $358M | 8.2% | ▼ 5.5% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $3.7B | 85.4% | ▲ 1.4% |
| Consumables (part of Products) | $3.2B | 87.0% | ▲ 2.3% |
| Instruments (part of Products) | $482M | 13.0% | ▼ 3.8% |
| Services | $634M | 14.6% | ▼ 11.5% |
| Region | Revenue | YoY |
|---|---|---|
| Americas | $2.4B | ▼ 1.4% |
| United States | $2.2B | ▼ 2.0% |
| Europe | $1.3B | ▲ 6.7% |
| Asia Pacific Middle East and Africa | $430M | ▼ 1.8% |
| China | $243M | ▼ 21.1% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Illumina, Inc.'s 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Illumina, Inc. | $4.54bn | 5.8% | 0.5% |
| Waters Corporation | $4.64bn | 52.5% | 15.8% |
| Mettler Toledo | $4.13bn | 6.9% | 1.5% |
| Charles River Laboratories | $4.00bn | -0.7% | -1.5% |
| Bruker Corp | $3.50bn | 1.6% | 8.8% |
| Avantor, Inc. | $6.64bn | 0.9% | -1.9% |
Compare with peers
- Waters Corporation revenue
- Mettler Toledo revenue
- Charles River Laboratories revenue
- Bruker Corp revenue
- Avantor, Inc. revenue
Head to head: ILMN vs WATILMN vs MTDCRL vs ILMN
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies